The overall RA disease activity score in this study measured by DAS28 was at the lower range and may reflect an effective treat-to-target treatment regime with good access to synthetic and biologic disease modifying anti-rheumatic drugs (respectively s-DMARDs and b-DMARDs)
BPC-157
Incretin-based GLP-1 therapies have additional effects, e.g., the reduction of glucagon, the slow down of gastric emptying, and inducing the sense of satiety
Databases showing substantial systematic error on the negative control outcomes, expressed as an absolute expected systematic error greater than 0.25, were also excluded
(2009) identified that after increasing the quantity of Bifidobacterium in the intestine, the content of proglucagon mRNA was higher, which promoted the secretion of glucagon-derived peptides
Risk of Neuropsychiatric Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists